“…Notably, the use of multi-thiol-reactive linkers has a remarkably long tradition, as an application for this purpose of the aromatic derivative, 1,3,5-tris(bromomethyl)benzene, was initially reported by Kemp & McNamara in 1985 (Kemp and McNamara, 1985) and use of its bis-reactive homologs, 1,2-bis(bromomethyl)benzene, and 1,3-bis(bromomethyl)benzene was described only few years later (Szewczuk et al, 1992). This methodology was also successfully applied in peptide drug development (Timmerman et al, 2007), including phage display (Angelini et al, 2012a; Baeriswyl et al, 2012; Baeriswyl et al, 2013; Baeriswyl and Heinis, 2013a; Baeriswyl and Heinis, 2013b; Bellotto et al, 2014; Chen et al, 2012; Chen et al, 2013; Chen et al, 2014b; Chen et al, 2014a; Heinis et al, 2009; Rentero-Rebollo et al, 2014; Timmerman et al, 2007) as well as peptide-albumin (Angelini et al, 2012c; Pollaro et al, 2014) and peptide-antibody drug conjugates (ADCs) (Angelini et al, 2012b). …”